Raport.

SOPHARMA AD (12/2018) Sales revenues for the first two months of 2018

Podstawa prawna: art. 17. 1 MAR.
Sofia, Bulgaria, March 6, 2018 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for February 2018 the Company recorded an increase of sales revenues of 2% compared to the same month of 2017, including 8% increase of domestic sales and same level of export sales.
For the first two months of this year, revenues from sales increased by 1% compared to the same period of 2017, including 2% increase of export sales and same level of domestic sales.

Lista plików:

  • Załącznik nr: 1

    Pobierz plik

    Sofia, Bulgaria www .sopharmagroup .com
    5 Lachezar Stanchev Str. tel: +359 (0) 2 4055 200; +359 (0) 8134 200
    Sopharma Business Towers , Tower А fax : +359 (0) 2 4055 141; +359 (0) 8134 141
    Sales revenues for February 2018
    Sofia, Bulgaria , March 6 , 2018 - Sopharma AD (3JR: “BSE -Sofia” AD, SPH: Warsaw
    Stock Exchange ) notifies that for February 2018 the Company recorded an increase of sales
    revenues of 2% co mpared to the same month of 2017, including 8 % increase of domestic
    sales and same level of export sales .
    For the first two months of this year, revenues from sales increased by 1 % compared to the
    same period of 2017 , including 2% increase of export sales and same level of domestic sales .
    Information about the company
    Sopharma AD
    85 years tradition and modern approach – modern production, European quality standards, corporate social
    responsibility. Sopharma has an active and crucial role in raising standards of everyday life, in making people healthier,
    happier and safer. Sopharma AD continuously invests in technologies, innova tion, research and science. We establish a
    constant and effective dialogue with all the actors in the pharmaceutical industry that contribute to the improvement of
    the health care system.
    The company produces and markets medicinal substances and dosage forms; conducts research, engineering and
    implementation activities in the field of phytochemistry, chemistry and pharmaceuticals. Sopharma AD provides services
    related to production, as wel l as to ancillary and service activities.
    The Company has a portfolio of more than 210 products: mainly generics and 15 original products, of which 12
    products are phyto -based.
    Sopharma Group
    Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as
    pharmaceuticals production , hospital supplies, pharmaceutical distribution (GDP standardized) and others. Sopharma and
    its production subsidiaries have 12 pharmaceutical plants in Bulgaria, compl ying with EU requi rements – GMP and a factory
    in Ukraine certified by local authorities.


    Treść w podglądzie może zawierać błędy powstałe podczas konwersji plików pdf.

Źródło: strona internetowa spółki, relacje inwestorskie, raporty bieżące i okresowe.

Oceń raport:


Pozytywny

Neutralny

Negatywny

WSZYSTKIE KOMUNIKATY SPÓŁKI
Informacje o spółce
Nazwa:Sopharma AD
ISIN:BG11SOSOBT18
NIP:
EKD:
Adres: 16 Iliensko Shosse Sofia
Telefon:+3592 8134200
www:www.sopharma.bg
Komentarze o spółce SOPHARMA AD
2019-11-21 02-11-41
tuInwestor
Nikt jeszcze nie skomentował tej spółki,
możesz być pierwszy.
Odpowiedzialność
prawna

Zgłoś moderatorowi
Copyright © 2017 tu Inwestor
PiriBit Sebastian Urbański
ul. Okopowa 113/19 p.1
91-849 Łódź
NIP: 888-28-35-649